Edwards Lifesciences (EW) Cost of Revenue (2009 - 2026)

Edwards Lifesciences has reported Cost of Revenue for 18 years, with the latest figure at $362.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 20.23% year-over-year to $362.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 23.23% YoY), and the FY2025 full-year result was $1.3 billion, up 19.39% from the prior year.
• Cost of Revenue for Q1 2026 stood at $362.6 million, up from $343.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $362.6 million in Q1 2026, with the low at -$98.8 million in Q4 2022.
• Average Cost of Revenue over 5 years is $272.1 million, with a median of $286.9 million recorded in 2024.
• Year-over-year, Cost of Revenue tumbled 131.92% in 2022 and jumped 354.05% in 2023.
• Tracing EW's Cost of Revenue over 5 years: stood at -$98.8 million in 2022, then surged by 354.05% to $251.0 million in 2023, then grew by 16.41% to $292.2 million in 2024, then grew by 17.39% to $343.0 million in 2025, then gained by 5.71% to $362.6 million in 2026.
• The last three Cost of Revenue figures came in at $362.6 million (Q1 2026), $343.0 million (Q4 2025), and $345.2 million (Q3 2025), per Business Quant data.

Peer Comparison